Blue Horseshoe Stocks

Big Options Winners & More

Options Reviews:

To begin this fresh trading week, we are going to recap some of the options trading ideas that we formulated in Friday morning’s premarket report. It was a solid finish for DIS, RIG, and ORCL, and a strong close to what was an exciting week.

Here are the major gains that we identified, as we’re strapping in for what promises to be another fruitful week of stock and options trading:

DIS Weekly $160-165 Calls
$160: 5.93-19.24 (+224%)
$162.50: 4.01-16.62 (+314%)
$165: 2.63-14.35 (+446%)
_____

RIG Weekly $2.50 Calls
$2.50: .06-.18 (+200%)
_____

ORCL Weekly $59.50-61 Calls
$59.50: .32-1.20 (+275%)
$60: .12-.69 (+475%)
$60.50: .05-.25 (+400%)
_____

Fresh Options Ideas:
LEGN Weekly $25-30 Calls
WB Weekly $40-41 Calls

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

The last time we checked in with PBIO, we assured our readers that we would promptly pass along any news updates that came down the pipe, and we have a fresh PR waiting for us as we kick off a fresh week this morning.

It alludes to a webcast conference that will be taking place on Thursday, which is of prime importance to both existing and prospective shareholders, and other members of the investment community. Details below on how to register for participation:

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) — Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.

Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET on Thursday, December 17th with the first live webcast at 9:30 AM ET.

REGISTER NOW AT : https://bit.ly/3oTRSRH

(>>View Full PR via OTCMARKETS)

Extended Watchlist:
AEPT, MJLB, SFOR, HAVLF, ZAAG, KGKG

ROKU Recap, Fresh Options Plays

Roku, Inc. ROKU – Recap

We’re going to close out this trading week by recapping the moves in the ROKU Calls we signaled for tracking on Wednesday morning. We were interested in the momentum that was built up in the stock over an extended period, and we took a shot with the ROKU Weekly $310-315 Calls.

Yesterday brought just the sort of activity we were looking for, mas ROKU posted a very nice move on the day, allowing for the following new highs and gain opportunities in those contracts:

ROKU Weekly $310-315 Calls
$310: 2.29-12.68 (+454%)
$315: 1.37-8.69 (+534%)

Fresh Options Ideas:

We have a large group of potential options plays as this trading week draws to a close, with several big name earnings reports dropping. Disney announced several new and highly anticipated shows to come in 2021 and is trading vigorously in the premarket. Here’s what we’re tracking heading into week’s end.

QIWI 01/15 $10-12.50
DIS Weekly $160-165 Calls*
RIG Weekly $2.50 Calls*
BTU 12/18 $2 Calls
ORCL Weekly $59.50-61 Calls*

*Please don’t attempt to trade options with a weekly expiration on a Friday unless you are a well-seasoned trader with access to disposable funds!

Extended Watchlist:
BSGM, HAVLF, DLOC, JNSH, KGKG

Updates on Stocks and Options

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

We have been looking closely at PBIO for a week now, first mentioning it last Wednesday the 2nd. We have seen some solid activity during that time frame, and wanted to circle back around this morning to deliver another video chart assessment of the chart.

We are also anticipating the company’s proposed acquisition partner Cannaworx, Inc. to commercially launch its patented immune booster supplement (ImmunaZin™) later this month, as indicated by the company on Friday. (>>View PR). We will certainly relay any updates on that to our readers if and when they become available.

Please take a moment to view the following presentation of today’s PBIO Chart:

View PBIO Chart

Strikeforce Technologies, Inc. SFOR

We included a mention of SFOR in yesterday morning’s premarket report, and the stock had one heck of an impressive performance on the day.

Shares of SFOR traded up from a low of .032 and reached as high as .115, which marked an intraday run of 259%, which came on huge volume of just over ten times the 30-day moving average. With momentum like that, we’ll certainly be interested in continuing to track its movements going forward.

Options Recaps

We also hit on a couple of really nice options ideas from yesterday’s report, which produced the following trading ranges and potential gain opportunities on the day:

ROKU Weekly $310-315 Calls
$310: 8.89-20.00 (+125%)
$315: 5.85-16.00 (+174%)
______

GME Weekly $15.50-14 Puts
$15.50: 1.29-2.04 (+58%)
$15: .94-1.62 (+72%)
$14.50: .71-1.20 (+69%)
$14: .35-.92 (+163%)
______

Fresh Options Ideas:
ASAN 12/18 $30-35 Calls

Options Recaps, Fresh Ideas

Options Reviews

We issued a couple of fresh options ideas in yesterday morning’s report, concerning SMAR and SFIX, which had both reported quarterly earnings in the premarket. We took interest in the SMAR 12/18 $70-75 Calls and the SFIX Weekly $45-50 Calls.

We witnessed good intraday performances in both cases, with SMAR outperforming SFIX, but not by a whole lot. Both plays will have provided our readers with plenty of opportunity to get in and out for some nice gains on the day.

Here were the total ranges and possible profits on those contracts:

SMAR 12/18 $70-75 Calls
$70: 2.10-6.80 (+136%)
$75: 1.11-3.65 (+219%)
_____

SFIX Weekly $45-50 Calls
$45: 5.00-7.99 (+136%)
$46: 4.46-7.29 (+219%)
$50: 1.90-4.59 (+222%)

Fresh Options Ideas:

GME Weekly $15.50-14 Puts
ZI 04/16 $45-50 Calls
SPLK Weekly $160 Calls
ROKU Weekly $310-315 Calls

Extended Watchlist:
CURR, SFOR, NECA, APYP, TLSS, BSSP

CURR Report, Options Ideas

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

Many of our regular readers will be familiar with CURE Pharmaceutical, a company that we profiled in a recent premarket report on November 25th. That morning, CURR shares registered a low of .99, and have made a pretty impressive move in the eight trading sessions since. Yesterday brought a new high of 1.82, which marks an overall increase of 83%

When we initially mentioned it, we looked at CURR as a possible bottom-play, which it certainly turned out to be. We would now classify it as a momentum mover, although as we’ve mentioned previously, there is an interesting backstory as well.

In our first report, we commented on the interesting proprietary technology the company had for vitamin/supplement delivery via orally-ingested film strips called Nutri-Strips. According to a recent statement from CURE CSO Nancy Duitch (CEO of The Sera Labs) the recent acquisition of The Sera Labs by CURE was primarily about assisting with and expediting the commercialization of Sera’s products that utilize this technology, which is referred to as RAD₃(Rapid Activation Delivery).

The first variety of oral supplements that CURE has made available via its online retail portal is a sleep aid, and according to the company, consumers can expect between three and six others to hit the storefront in early 2021.

The roll-out and advertising campaigns designed by CURE for the emerging lines have been described by company officials as aggressive. It has been less than six months since the original announcement of the acquisition of The Sera Labs, so we would submit that aggressive is an appropriate characterization. Speaking of which, CURE has released another PR update this morning, announcing a partnership with a blockbuster movie star which we will share below.

Fresh CURR News:

LOS ANGELES & OXNARD, Calif.–(BUSINESS WIRE)–CURE Pharmaceutical Holdings (OTCMKTS: CURR) wholly owned subsidiary, The Sera Labs, Inc., has enlisted Oscar, Golden Globe and Emmy Award-winning Nicole Kidman as the brand’s first-ever strategic business partner and global brand ambassador for their topical products. In addition to being the face of the brand, Kidman will play an integral role in the strategic direction of product development and messaging.

“The partnership with SeraLabs was an easy decision for me,” states Kidman, SeraLabs Strategic Partner and Global Brand Ambassador. “With my injury last year, I experienced the benefit of CBD wellness products firsthand. I believe these products are a vital solution in health and wellness and Nancy and SeraLabs are a company I believe in. Joining them in this partnership is something I am very excited about!” (>>View Full PR)

CURR Video Chart:

We would suggest our readers take a moment to view the video presentation we’ve prepared for the current CURR chart, which has recently broken through the key resistance areas we highlighted in our previous report.

CURR Video Chart

For All Investor Inquiries on CURR,Contact:
Gary Zwetchkenbaum, Plum Tree Consulting LLC
Email: gzplumtree@gmail.com
Phone: (516) 455-7662
Web: plumtreeconsultingllc.com

Fresh Options Ideas:

We’ve also identified a couple of solid looking potential plays on the big board earnings calendar this morning:

SMAR 12/18 $70-75 Calls
SFIX Weekly $45-50 Calls